– Enrolment completed – 120 patients with end-stage renal disease in 22 centers in Europe – Primary endpoint readouts anticipated in Q2 2025, first market approval expected in 2026 – Capability to obtain market approval is further strengthened with the appointment of Rob Eyers as Chief…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.